Scott R. Armstrong

The 5‐HT₄ receptor agonist, tegaserod, is a potent 5‐HT_2B receptor antagonist <i>in vitro</i> and <i>in vivo</i>

David T. Beattie, Jacqueline A.M. Smith, Daniel G. Marquess et al. · British Journal of Pharmacology · 2004 · 119 citations · Full text

Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat

Laxminarayan G. Hegde, Cecile Yu, Travis Renner et al. · Journal of Cardiovascular Pharmacology · 2011 · 64 citations

Hypertension, Cardiovascular Pharmacology, Pharmacotherapy +17

The in vivo gastrointestinal activity of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity

David T. Beattie, Scott R. Armstrong, J P Shaw et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2008 · 46 citations

Signal Transduction, Functional Selectivity, Gastrointestinal Pharmacology +8

The Pharmacology of TD-8954, a Potent and Selective 5-HT4 Receptor Agonist with Gastrointestinal Prokinetic Properties

David T. Beattie, Scott R. Armstrong, Ross G. Vickery et al. · Frontiers in Pharmacology · 2011 · 42 citations · Full text

Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT4 receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation

Daniel D. Long, Scott R. Armstrong, David T. Beattie et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 22 citations · Full text

Functional Gastrointestinal Disorder, Gastrointestinal Pharmacology, Medicine +8